Phase I Trial Design and Methodology for Anticancer Drugs
作者： Patrick V. Acevedo , Deborah L. Toppmeyer , Eric H. Rubin
DOI: 10.1007/978-1-59259-739-0_17
关键词:
摘要: Phase I trials play a pivotal role in the introduction of new anticancer drugs into clinic, and there are important ethical differences between phase oncology involving normal volunteers. In addition, recent advances cancer biology have resulted many drug targets led to approaches trial design. Although may involve Food Drug Administration (FDA)-approved (used schedules or combinations), this chapter reviews objectives, design, methodology, ethics for single investigational compound.
springer.com
sci-hub.st 参考文章(35)
E. Wasserman, A. Myara, F. Lokiec, F. Goldwasser, F. Trivin, M. Mahjoubi, J.L. Misset, E. Cvitkovic, Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports Annals of Oncology. ,vol. 8, pp. 1049- 1051 ,(1997) , 10.1023/A:1008261821434
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, Jaap Verweij, Martine Van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther, New Guidelines to Evaluate the Response to Treatment in Solid Tumors JNCI: Journal of the National Cancer Institute. ,vol. 92, pp. 205- 216 ,(2000) , 10.1093/JNCI/92.3.205
R. Simon, L. Rubinstein, S. G. Arbuck, M. C. Christian, B. Freidlin, J. Collins, Accelerated Titration Designs for Phase I Clinical Trials in Oncology Journal of the National Cancer Institute. ,vol. 89, pp. 1138- 1147 ,(1997) , 10.1093/JNCI/89.15.1138
R. Mick, M. J. Ratain, Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased Precision Journal of the National Cancer Institute. ,vol. 85, pp. 217- 223 ,(1993) , 10.1093/JNCI/85.3.217
Joseph P. Eder, Jeffrey G. Supko, Jeffrey W. Clark, Thomas A. Puchalski, Rocio Garcia-Carbonero, David P. Ryan, Lawrence N. Shulman, Joann Proper, Moira Kirvan, Barbara Rattner, Susan Connors, Mary T. Keogan, Milos J. Janicek, William E. Fogler, Lowell Schnipper, Nancy Kinchla, Carolyn Sidor, Eric Phillips, Judah Folkman, Donald W. Kufe, Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily Journal of Clinical Oncology. ,vol. 20, pp. 3772- 3784 ,(2002) , 10.1200/JCO.2002.02.082
Ying Kuen Cheung, Rick Chappell, Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities Biometrics. ,vol. 56, pp. 1177- 1182 ,(2000) , 10.1111/J.0006-341X.2000.01177.X
A. B. Miller, B. Hoogstraten, M. Staquet, A. Winkler, Reporting results of cancer treatment Cancer. ,vol. 47, pp. 207- 214 ,(1981) , 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Anthony W. Tolcher, Chris H. Takimoto, Eric K. Rowinsky, The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"? Journal of Clinical Oncology. ,vol. 20, pp. 4276- 4278 ,(2002) , 10.1200/JCO.2002.20.21.4276
A I Richards, Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine. Journal of Clinical Oncology. ,vol. 13, pp. 2476- 2476 ,(1995) , 10.1200/JCO.1995.13.9.2476
Brian J. Druker, Moshe Talpaz, Debra J. Resta, Bin Peng, Elisabeth Buchdunger, John M. Ford, Nicholas B. Lydon, Hagop Kantarjian, Renaud Capdeville, Sayuri Ohno-Jones, Charles L. Sawyers, Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia The New England Journal of Medicine. ,vol. 344, pp. 1031- 1037 ,(2001) , 10.1056/NEJM200104053441401